Compare OLB & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLB | ADVB |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 8.4M |
| IPO Year | N/A | 2025 |
| Metric | OLB | ADVB |
|---|---|---|
| Price | $0.90 | $0.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.1K | ★ 1.3M |
| Earning Date | 11-14-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,639,651.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.31 |
| 52 Week High | $2.50 | $4.10 |
| Indicator | OLB | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 37.20 |
| Support Level | $0.90 | $0.31 |
| Resistance Level | $1.02 | $0.40 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 3.89 | 31.20 |
The OLB Group Inc is a diversified fintech e-commerce merchant services provider and Bitcoin crypto mining enterprise. It focuses on a suite of products in the merchant services marketplace and seeks to provide integrated business solutions to merchants throughout the United States. Along with its subsidiaries, the company offers a cloud-based business management platform that provides turnkey solutions for merchants to enable them to build and manage their retail businesses, whether online or at a brick-and-mortar location, payment processing solutions, payment gateway, virtual terminal with proprietary business management tools, and crowdfunding solutions. The company has two business segments; Fintech Services which generates key revenue, and the Bitcoin Mining business segment.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.